Durvalumab (Imfinzi), Carboplatin, Paclitaxel

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses durvalumab (Imfinzi) 50 mg/mL, concentrate for IV infusion. Indication: Durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer who are candidates for systemic therapy, followed by durvalumab as monotherapy.